Ophthalmology

R. Theodore Smith MD, PhD, professor of ophthalmology at the Icahn School of Medicine at Mount Sinai discusses new research to reduce the burden of AMD and how imaging can revolutionize the retina space.

David Brown, a retina specialist discusses how retina and diabetes specialists can coordinate care and education for their patients as well as the outlook for AMD/DME research.

In a phase 2 study, a long-acting, implantable delivery system for ranibizumab allowed patients with wet age-related macular degeneration to go up to 15 months before requiring a refill.

Dilsher Dhoot, MD, discusses the avenues where future research for diabetic macular edema will focus

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

Yutiq, a fluocinolone acetonide intravitreal implant, is indicated for the treatment of chronic non-infectious uveitis that affects the posterior segment of the eye.

A comparison of patients in a pair of European-based studies tracking adherence to the diet found those eating healthier were significantly less likely to develop late-stage AMD.

Novartis files new indication for ranibizumab (Lucentis) for the treatment of retinopathy of prematurity.

Zinc is the second most abundant trace element in the human body after iron, and is present in high concentration in the human eye.

There is a found significant unmet need to develop treatments that limit or protect against scar formation, GA development, retinal thinning, fluid increase, and lesions, as an accompaniment to anti-VEGF therapy.

The findings lend to investigators believe that earlier endpoints for AMD diagnosis are needed.

In animal models, not only did the drug help protect apelin function-deficient models from laser-induced choroidal neovascularization, but it did it through unique mechanisms that were independent of VEGF function.

The Novartis humanized single-chain antibody fragment previously showed improved best corrected visual acuity in patients with nAMD versus aflibercept.

Computers can do as well as clinicians in diagnosing age-related macular degeneration, say investigators who have developed tools based on artificial intelligence to detect the disorder.

The latanoprost ophthalmic emulsion solution reduced intraocular pressure in patients by a mean 6-8 mmHg from baseline in clinical trials.

Onchocerciasis, also known as river blindness, may now be detectable through a urine diagnostic developed by investigators from Scripps Research Institute.

The FDA has granted a rare pediatric disease designation to Lin BioScience’s LBS-008 for the treatment of Stargardt disease.

Investigators reported an overall mean estimation error ranging from 3.47% to 5.29% in five-year outcomes for patients with AMD.

The acceptance comes less than a month since the FDA had approved the anti-VEGF therapy for the treatment of wet AMD. Its mechanism of action allows it to block new blood vessel growth and the passing of fluids through blood vessels in the eye.

ProQR Therapeutics has announced positive interim results from its phase 1/2 clinical trial evaluating QR-110 as a potential treatment for Leber’s congenital amaurosis 10 (LCA10).

A recent study found the costs of medical, laser, and surgical interventions were 2.5% or more of the median annual household income for many patients worldwide.

Among patients who were lost to follow-up over a year, just 7.4% attended a follow-up visit after the observed 12 months. In the total loss to follow-up patient population, they reported a mean 7.8 injection treatments and 8.5 clinic visits. In patients not lost, they reported a mean 14.3 injections and 17.1 visits.

The COMPASS-XT five-year analysis reported that patients treated with the micro-stent experienced statistically significant loss of endothelial cells compared to the patients treated with lone cataract surgery.

The Kala Pharmaceuticals therapy INVELTYS becomes the first twice-daily ocular corticosteroid indicated for such treatment.

Oxervate eye drops, which contain cenegermin, are the first approved treatment for a rare condition that affects fewer than 5 in 10,000 individuals.

A peer-reviewed manuscript outlines the preclinical validation for the use of QR-110 in the treatment of Leber’s congenital amaurosis 10 (LCA10).

A modified 12-week dosing schedule is now available for physicians administering the vascular endothelial growth factor (VEGF) inhibitor to patients with wet age-related macular degeneration.

The results of a new study point to age-related macular degeneration, diabetic retinopathy, and glaucoma as potential early warning signs that an individual is at risk for developing Alzheimer disease or dementia.

In an effort to reprogram retina cell regeneration, investigators activated dormant stem cells then aided other stem cells in developing into rod photoreceptor cells—the most abundant cell type in the retina which first aid the retina in sensing light.

A post-hoc analysis of data from the TREX-AMD trial has determined that eyes with neovascular age-related macular degeneration and treated with ranibizumab, develop more macular atrophy lesions within baseline choroidal neovascularization regions than outside those regions.